At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 900 enrolled
Drug / intervention
Erenumab +1 morebiological
Likely dose
Erenumab 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)
In Brief
A Phase 3 clinical trial evaluating Erenumab and Placebo for Episodic Migraine. Completed, enrolled 900 participants across 81 sites in 11 countries.
Detailed Summary
This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisodic Migraine
CountriesArgentina, India, Lebanon, Malaysia, Mexico, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartFeb 2018
Primary CompletionJan 2020
TodayJul 2026
First PostedNov 6, 2017
Enrollment StartFeb 8, 2018
Primary CompletionJan 13, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.7 years ago
Interventions
Erenumabbiological
70 mg/mL pre-filled syringe administered subcutaneously
Placeboother
Matching placebo in pre-filled syringe administered subcutaneously